BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at the BMO Capital
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017 .
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2017 .
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 1, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
— Study Showed that Six Months of AR101 Treatment Could Significantly Reduce Clinical Reactivity to Peanut in Approximately 80 Percent of Subjects Enrolled — — First Peer-Reviewed Publication of Efficacy and Safety of an Industry-Sponsored Food Allergy Trial — BRISBANE, Calif.
— Poster Presentations Will Discuss Global Screening Data from Aimmune’s Phase 3 PALISADE Trial and Current Approaches to Oral Immunotherapy — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 19, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for
— Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients — — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment — — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m.
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at three upcoming investor
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the 2017 Wedbush PacGrow Healthcare
BRISBANE, California --(BUSINESS WIRE)--Aug. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017 .
